Phenethylamine compounds salts, polymorphic forms and methods of use thereof
Disclosed herein are salts and solid forms of MDMA, (R)-MDMA, (S)-MDMA, MDE, S-MDE, R-MDE, MDAI, MBDB, S-MBDB, R-MBDB, MEAI, and 5,6-Dimethoxy-2-aminoindane, including salts, solid forms of the compound and salts thereof, as well as polymorphs of solid forms. The solid forms disclosed herein may have improved properties, such as improved physical, chemical, and/or pharmacokinetic properties. Also disclosed are methods for making the salts and solid forms and methods for administering the same. The disclosed salt and solid forms of MDMA, (R)-MDMA, (S)-MDMA, MDE, S-MDE, R-MDE, MDAI, MBDB, S-MBDB, R-MBDB, MEAI, and 5,6-Dimethoxy-2-aminoindane may be useful for treating neurological disease and/or a psychiatric disorder in a subject.
1. A solid form of 3,4-methylenedioxy-methamphetamine (MDMA) hemifumarate salt, wherein the solid form is characterized by two or three XRPD signals selected from the group consisting of 17.3° 2θ, 18.6° 2θ, and 21.9° 2θ (±0.2° 2θ; ±0.1° 2θ; or ±0.0° 2θ; Cu Kα1 radiation).
2. The solid form of MDMA hemifumarate salt of claim 1 , wherein the solid form of MDMA hemifumarate is characterized by three or more XRPD signals selected from the group consisting of 17.3° 2θ, 18.6° 2θ, 21.9° 2θ, 10.9° 2θ, 13.1° 2θ, 16.7° 2θ, and 19.2° 2θ (±0.2° 2θ; ±0.1° 2θ; or ±0.0° 2θ; Cu Kα1 radiation).
3. The solid form of MDMA hemifumarate salt of claim 1 , wherein the solid form of MDMA hemifumarate is characterized by three or more XRPD signals selected from the group consisting of 17.3° 2θ, 18.6° 2θ, 21.9° 2θ, 10.9° 2θ, 13.1° 2θ, 16.7° 2θ, 19.2° 2θ, and 8.4° 2θ, (±0.2° 2θ; ±0.1° 2θ; or ±0.0° 2θ; Cu Kα1 radiation).
4. The solid form of MDMA hemifumarate salt of claim 1 , wherein the solid form of MDMA hemifumarate is characterized by two or more XRPD signals in Table 2 (±0.2° 2θ; ±0.1° 2θ; or ±0.0° 2θ; Cu Kα1 radiation).
5. The solid form of MDMA hemifumarate salt of claim 1 , wherein the solid form of MDMA hemifumarate is characterized by a XRPD pattern substantially similar to that shown in FIG. 1 .
6. The solid form of MDMA hemifumarate salt of claim 1 , wherein the solid form of MDMA hemifumarate is further characterized by a TGA diagram having an onset at about 179.0° C.
7. The solid form of MDMA hemifumarate salt of claim 1 , wherein the solid form of MDMA hemifumarate is further characterized by a TGA profile substantially similar to that shown in FIG. 45 and/or a DSC profile substantially similar to that shown in FIG. 45 .
8. A pharmaceutical composition comprising the solid form of claim 1 , and a pharmaceutically acceptable excipient.
9. A method of treating post-traumatic stress disorder (PTSD) in a subject in need thereof, comprising administering to the subject the solid form of claim 1 .
10. A solid form of 3,4-methylenedioxy-methamphetamine (MDMA) hemifumarate salt, wherein the solid form is characterized by two or three XRPD signals selected from the group consisting of 10.9° 2θ, 13.1° 2θ, and 16.7° 2θ (±0.2° 2θ; ±0.1° 2θ; or ±0.0° 2θ; Cu Kα1 radiation).
11. The solid form of MDMA hemifumarate salt of claim 10 , wherein the solid form of MDMA hemifumarate is characterized by three or more XRPD signals selected from the group consisting of 10.9° 2θ, 13.1° 2θ, 16.7° 2θ, 17.3° 2θ, and 18.6° 2θ (±0.2° 2θ; ±0.1° 2θ; or ±0.0° 2θ; Cu Kα1 radiation).
12. A pharmaceutical composition comprising the solid form of claim 10 , and a pharmaceutically acceptable excipient.
13. A method of treating PTSD in a subject in need thereof, comprising administering to the subject the solid form of claim 10 .
14. A solid form of 3,4-methylenedioxy-methamphetamine (MDMA) hemifumarate salt, wherein the solid form is characterized by two or three XRPD signals selected from the group consisting of 16.7° 2θ, 18.6° 2θ, and 21.8° 2θ (±0.2° 2θ; ±0.1° 2θ; or ±0.0° 2θ; Cu Kα1 radiation).
15. The solid form of MDMA hemifumarate salt of claim 14 , wherein the solid form of MDMA hemifumarate is characterized by three or more XRPD signals selected from the group consisting of 16.7° 2θ, 18.6° 2θ, 21.8° 2θ, 18.2° 2θ, and 19.1° 2θ (±0.2° 2θ; ±0.1° 2θ; or ±0.0° 2θ; Cu Kα1 radiation).
16. The solid form of MDMA hemifumarate salt of claim 14 , wherein the solid form of MDMA hemifumarate is characterized by three or more XRPD signals selected from the group consisting of 16.7° 2θ, 18.6° 2θ, 21.8° 2θ, 18.2° 2θ, 19.1° 2θ, 8.3° 2θ, 10.9° 2θ, and 13.0 ° 2θ (±0.2° 2θ; ±0.1° 2θ; or ±0.0° 2θ; Cu Kα1 radiation).
17. The solid form of MDMA hemifumarate salt of claim 14 , wherein the solid form of MDMA hemifumarate is characterized by three or more XRPD signals selected from the group consisting of 16.7° 2θ, 18.6° 2θ, 21.8° 2θ, 17.3° 2θ, and 18.2° 2θ (±0.2° 2θ; ±0.1° 2θ; or ±0.0° 2θ; Cu Kα1 radiation).
18. The solid form of MDMA hemifumarate salt of claim 14 , wherein the solid form of MDMA hemifumarate is characterized by two or more XRPD signals in Table 64 or Table 65 (±0.2° 2θ; ±0.1° 2θ; or ±0.0° 2θ; Cu Kα1 radiation).
19. The solid form of MDMA hemifumarate salt of claim 14 , wherein the solid form of MDMA hemifumarate is characterized by a XRPD pattern substantially similar to that shown in FIG. 115 or FIG. 116 .
20. A pharmaceutical composition comprising the solid form of claim 14 , and a pharmaceutically acceptable excipient.
21. A method of treating PTSD in a subject in need thereof, comprising administering to the subject the solid form of claim 14 .
22. A solid form of 3,4-methylenedioxy-methamphetamine (MDMA) hemifumarate salt, wherein the solid form is characterized by two or three XRPD signals selected from the group consisting of 10.9° 2θ, 18.6° 2θ, and 21.9° 2θ (±0.2° 2θ; ±0.1° 2θ; or ±0.0° 2θ; Cu Kα1 radiation).
23. The solid form of MDMA hemifumarate salt of claim 22 , wherein the solid form of MDMA hemifumarate is characterized by three or more XRPD signals selected from the group consisting of 10.9° 2θ, 18.6° 2θ, 21.9° 2θ, 13.1° 2θ, 16.7° 2θ, and 17.3° 2θ (±0.2° 2θ; ±0.1° 2θ; or ±0.0° 2θ; Cu Kα1 radiation).
24. A pharmaceutical composition comprising the solid form of claim 22 , and a pharmaceutically acceptable excipient.
25. A method of treating PTSD in a subject in need thereof, comprising administering to the subject the solid form of claim 22 .